Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment
Public ClinicalTrials.gov record NCT01104662. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia Among Subjects With Moderate or Severe Renal Impairment
Study identification
- NCT ID
- NCT01104662
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Enrollment
- 92 participants
Conditions and interventions
Interventions
- Vancomycin Drug
- Daptomycin Drug
- Semi-Synthetic Penicillin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 18, 2010
- Primary completion
- Jun 11, 2012
- Completion
- Jun 11, 2012
- Last update posted
- Sep 4, 2018
2010 – 2012
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Azusa | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Torrance | California | — | — |
| Not listed | Washington D.C. | District of Columbia | — | — |
| Not listed | Decatur | Georgia | — | — |
| Not listed | Somers Point | New Jersey | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Columbus | Ohio | — | — |
| Not listed | West Reading | Pennsylvania | — | — |
| Not listed | Mission | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01104662, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 4, 2018 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01104662 live on ClinicalTrials.gov.